Allosteric modulators: The new generation of receptor antagonist

Molecular Interventions

Volumn 4, Issue 4, 2004, Pages 222-229

  Kenakin, Terry P ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4 METHYL 4 PIPERIDINYL] 2 METHYL 1 [1 [4 (TRIFLUOOROMETHYL)PHENYL]ETHYL]PIPERAZINE; ACETYLCHOLINE; ADRENERGIC RECEPTOR; ALCURONIUM; ANTIVIRUS AGENT; ARECOLINE; BETHANECHOL; BRUCINE; CARBACHOL; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DOPAMINE RECEPTOR; METHYLFURTRETHONIUM; METHYLSCOPOLAMINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N (2,3 DIPHENYL 1,2,4 THIADIAZOL 5(2H) YLIDENE)METHANAMINE; OPIATE RECEPTOR; OXOTREMORINE; PILOCARPINE; RECEPTOR BLOCKING AGENT; STRYCHNINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBURNINE; VINCAMINE; VIRUS ENVELOPE PROTEIN;

ALLOSTERISM; ALZHEIMER DISEASE; CHEMICAL MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIGAND BINDING; NONHUMAN; PROTEIN CONFORMATION; PROTEIN STRUCTURE; RECEPTOR INTRINSIC ACTIVITY; REVIEW; VIRUS RESISTANCE;

ALLOSTERIC REGULATION; HUMANS; PROTEIN BINDING; RECEPTORS, CELL SURFACE;

EID: 4444324531     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.4.4.6     Document Type: Review

References (35)

1. Ehlert, F. J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33, 187-194 (1988).
2. Maeda, K., Nakata, H., Koh, Y. et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. (in press).
3. Jakubic, J., Bacakova, L., Lisa, V., El-Fakahany, E.E., and Tucek, S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 53, 172-179 (1997).
4. Lazareno, S., Gharagozloo, P., Kuonen, D., Popham, A. and Birdsall, N.J.M. Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: Radioligand binding studies. Mol. Pharmacol. 53, 573-589 (1998).
5. Hejnova, L., Tucek, S., and El-Fakahany, E.E. Positive and negative allosteric interactions on muscarinic receptors. Eur. J. Pharmacol. 291, 427-430 (1995).
6. Kazmierski, W.M., Boone, L., Lawrence, W., Watson, C., and Kenakin, T. CCR5 2002. Chemokine receptors: Gatekeepers of HIV-1 infection. Curr. Drug Targets Infect. Disord. 2, 265-278 (2002).
7. Burgen, A.S.V. Conformational changes and drug action. Fed. Proc. 40, 2723-2728 (1966).
8. Hilser, V.J. and Freire, E. Structure-based calculation of the equilibrium folding pathway of proteins: Correlation with hydrogen exchange protection factors. J. Mol. Biol. 262, 756-772 (1996).
9. Hilser, V.J. and Freire, E. Predicting the equilibrium protein folding pathway: Structure-based analysis of staphylococcal nuclease. Proteins 27, 171-183 (1997).
10. Hilser, V.J., Townsend, B.D., and Freire, E. Structure-based statistical thermodynamic analysis of T4 lysozyme mutants: Structural mapping of cooperative interactions. Biophys. Chem. 64, 69-79 (1997).
11. Hilser, V.J., Dowdy, D., Oas, T.G., and Freire, E. The structural distribution of cooperative interactions in proteins: Analysis of the native state ensemble. Proc. Natl. Acad. Sci. USA 95, 9903-9908 (1998).
12. Frauenfelder, H., Parak, F., and Young, R.D. Conformational substrates in proteins. Ann. Rev. Biophys. Biophys. Chem. 17, 451-479 (1988).
13. Frauenfelder, H., Sligar, S.G., and Wolynes, P.G. The energy landscapes and motions of proteins. Science 254, 1598-1603 (1991).
14. Kenakin, T. Efficacy at G protein-coupled receptors. Nat. Rev. Drug Discov. 1, 103-109 (2002).
15. Kenakin, T.P. Drug efficacy at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 42, 349-379 (2002).
16. Connor, R.I., Sheridan, K.E., Ceradini, D., Choe, S., and Landau, N.R. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J. Exp. Med. 185, 621-628 (1997).
17. Cocchi, F., DeVico, A.L., Garzino-Demo, A., Cara, R.C., and Lusso, P. The V3 domain of the HIV gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2, 1244-1247 (1996).
18. Choe, H., Farzan, M., Sun, Y. et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135-1148 (1996).
19. Bieniasz, P.D., Fridell, R.A., Aramori, I., Ferguson, S.S., Caron, M.G., and Cullen, B.R. HIV-1 induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J. 16, 2599-2609 (1997).
20. Domingo, E., Menendez-Arias, L., Quinones-Mateu, M. E., Holguin, A., Gutierrez-Rivas, M., Martinez, M. A., Quer, J., Novella, I. S., and Holland, J. J. Viral quasispecies and the problem of vaccine-escape and drug resistant mutants. Prog. Drug. Res. 48, 99-128 (1997).
21. Harrigan, P.R., Bloor, S., and Larder, B.A. Relative replicative fitness of zidoviudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72, 3773-3778 (1998).
22. Schols, D., Este, J.A., Cabrera, C., and De Clercq, E. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J. Virol. 72, 4032-4037 (1998).
23. Mosier, D.E., Picchio, G.R., Gulizia, R.J., Sabbe, R., Poignard, P., Picard, L., Offord, R.E., Thompson, D.A., and Wilken, J. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73, 3544-3550 (1999).
24. Trkola, A., Kuhmann, S.E., Strizki, J.M. et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. USA 99, 395-400 (2002).
25. Lazareno, S. and Birdsall, N.J.M. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 48, 362-378 (1995).
26. Tucek, S. and Proska, J. Allosteric modulation of muscarinic acdetylcholine receptors. Trends Pharmacol. Sci. 16, 205-212 (1995).
27. Fawzi, A.B., MacDonald, D., Benbow, L.L. et al. SCH-202676: An allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol. Pharmacol. 59, 30-37 (2001).
28. Bartus, R.T., Dean, R.L., Beer, B., and Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-417 (1982).
29. Maelicke, A., Schrattenholz, A., Samochocki, M., Radina, M., and Albuquerque, E.X. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav. Brain Res. 113, 199-206 (2000).
30. Rogers, S.L., Farlow, M.R., Doody, R.S., Mohs, R., and Friedhoff, L.TA 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50, 136-145 (1998).
31. Maelicke, A., and Albuquerque, E.X. New approach to drug therapy of Alzheimer's dementia. Drug Discov. Today 1, 53-59 (1996).
32. Krause, R.M., Buisson, B., Bertrand, S., Corringer, P.-J., Galzi, J.-L., Changeuz, J.-P. and Bertrand, D. Ivermectin A positive allosteric effector of the a7 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53, 283-294 (1998).
33. Hall, D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: An extension of the two-state model of receptor activation. Mol. Pharmacol. 58, 1412-1423 (2000).
34. Litschig, S., Gasparini, F., Rueegg, D. et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. 55, 453-461 (1999).
35. Rees, S., Morrow, D., and Kenakin, T. GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels 8, 261-268 (2002).